KRAS and pancreatic neoplasm: This has the potential to treat even advanced disease; indeed, a recently published case report highlighted the ability of Kirsten rat sarcoma virus (Kras) G12D mutation-targeting TCR-T to mediate regression of metastatic pancreatic cancer, with the response ongoing 6 months post-treatment (3).